ADDRESSING SHORT-ACTING- BETA-AGONIST (SABA) RELIEVER OVERUSE AND OVER-RELIENCE IN ASTHMA

‘Reforming health systems:
a short film

Zero tolerance for asthma attacks

AN URGENT CALL FOR HEALTH SYSTEM CHANGE

Of the 339 million (4% of population) individuals affected by asthma,8 50–75% have mild asthma,9 defined as asthma that can be controlled with reliever medication used alone or low doses of controller medication used with Short-Acting Beta-Agonist (SABA) as needed.2,10 Despite advances in medication and new treatment guidelines,2 national and international surveys have revealed inadequate asthma control in 40-50% of patients.11,12 This means that almost 150 million could be living at risk of a potentially avoidable asthma attack which may require hospital treatment and care.13

Inflammation is the underlying cause of asthma,14 however, patients tend to rely acutely upon their SABA reliever, which has no inherent anti-inflammatory properties.15 When symptoms worsen, patients tend to increase use of their blue SABA inhaler use which can unintentionally lead to over-reliance.15,16

Approximately 9–38% of all patients in the EU with asthma over-used their SABA17 (based on ≥3 SABA canisters per year) which increases their risk of exacerbations3 (asthma attacks) and even death.18

AS AN ADVOCATE FOR BETTER ASTHMA CARE, WATCH THIS VIDEO TO SEE HOW FURTHER COLLABORATION CAN EMBED A NEW ERA OF ASTHMA MANAGEMENT IN YOUR HEALTH SYSTEM POST COVID-19

TAKE ACTION

HELP TACKLE PREVENTABLE ASTHMA ATTACKS

THERE IS A NEED FOR POLICYMAKER ACTION TO REDUCE SABA OVER-RELIANCE, INTRODUCE POLICIES THAT MONITOR ITS USE, AND PROMPT GREATER ADOPTION OF MEDICINES WHICH TREAT THE UNDERLYING DISEASE, AS WE MOVE OUT OF THE COVID-19 PANDEMIC

THROUGH THIS, SABA MIGHT LOSE ITS ‘KEY MEDICATION’ STATUS19 IN THE MINDS OF PATIENTS, POTENTIALLY LEADING TO MULTIPLE BENEFITS

AN URGENT PRIORITY

THE IMPACT ON HEALTH SYSTEMS AND VALUE FOR CHANGE

The cost of persistent asthma in Europe

Adapted from Accordini, S., A. G. Corsico, M.Braggion, M.et al.(2013)24

Patients should not die of avoidable asthma attacks, yet asthma mortality has remained stubbornly high and patients continue to sadly die

Watch Dawn’s story to see where an improved health system that is designed to better manage asthma could have made a life-changing difference

REWIRE SYSTEMS

HEALTH SYSTEM CHANGE IS CRUCIAL

references

  • 1Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046.
  • 2Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. Available at: https:// ginasthma.org/wp-content/uploads/2020/04/GINA-2020- full-report_-final-_wms.pdf
  • 3Stanford, R.H.; Shah, M.B.; D’Souza, A.O.; Dhamane, A.D.; Schatz, M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann. Allergy Asthma Immunol. 2012, 109, 403–407
  • 4Suissa, S.; Ernst, P.; Kezouh, A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002, 57, 880–884
  • 5Suissa, S.; Ernst, P.; Benayoun, S.; Baltzan, M.; Cai, B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000, 343, 332–336
  • 6Blakeston S, Harper G, Zabala Mancebo J. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma [published online ahead of print, 2020 May 29].J Asthma.2020;1 - 8
  • 7Martin MJ, Harrison TW. Is it time to move away from short- acting beta-agonists in asthma management?. Eur Respir J. 2019;53(4):1802223.
  • 8Global Asthma Network. The Global Asthma Report 2018. Available online via: http://www.globalasthmanetwork.org/ Global%20Asthma%20Report%202018.pdf Last accessed June 2020
  • 9Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations [published correction appears in Allergy. 2007 Aug;62(8):968. de Lara, M T [corrected to Tunon de Lara, M]]. Allergy. 2007;62(6):591-604
  • 10Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018;378(20):1877-1887
  • 11Price D, Fletcher M, Der Molen T. Asthma Control and management in 8,000 European patients: the Recognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014; 24: 14009
  • 12Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross- sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66-74.
  • 13Nunes, C., Pereira, A.M. & Morais-Almeida, M. Asthma costs and social impact. asthma res and pract 3, 1 (2017).
  • 14Beasley R, et al. Pathology of asthma and its clinical implications. Journal of Allergy and Clinical Immunology 1993;92:148-154
  • 15O’Byrne PM, Jenkins C and Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50:1701103
  • 16Patel M, Pilcher J, Reddel HK et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin. Exp. Allergy. 2013;43:1144–1151
  • 17Janson, C., Menzies-Gow, A., Nan, C. et al. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Adv Ther 37, 1124–1135 (2020)
  • 18Suissa S, Ernst P, Boivin J-F, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604-610
  • 19Charriot J, Gaga M, Suehs C, Bourdin A. Asthma rescue treatments, time to reboot. Eur Respir J. 2020;55(4):2000542. Published 2020 Apr 16.
  • 20Mukherjee, M., Stoddart, A., Gupta, R.P. et al. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med 14, 113 (2016). https://doi.org/10.1186/s12916-016-0657-8
  • 21AstraZeneca Pharmaceuticals LP. Data on file, Budesonide/ formoterol: Annual Rate of Exacerbations Globally (ID:SD- 3010-ALL-0017)
  • 22Sastre J, Fabbri LM, Price D, et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J. 2016;9:13. Published 2016 May 4. doi:10.1186/s40413- 016-0105-4
  • 23Accordini S, Bugiani M, Arossa W, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol. 2006;141(2):189-198.
  • 24Accordini, S., A. G. Corsico, M. Braggion, M. W. Gerbase, D. Gislason, A. Gulsvik, J. Heinrich, C. Janson, D. Jarvis, R. J. I. a. o. a. Jõgi and immunology (2013). “The cost of persistent asthma in Europe: an international population-based study in adults.” 160(1): 93-101
  • 25Santos LA, Oliveira MA, Faresin SM, et al. Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients. Braz J Med Biol Res. 2007;40(7):943-948.
  • 26Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J. 2010;17(2):74-80
  • 27Moullec G, FitzGerald JM, Rousseau R, et al. Economic Burden of Asthma (EBA) study team. Interaction e ect of psychological distress and asthma control on productivity loss?. Eur Respir J. 2015;45(6):1557-1565